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Bartonella bacilliformis is the etiologic agent of Carrión’s disease or Oroya fever. B. bacilliformis infection represents an interesting
model of human host specificity. The notable differences in clinical presentations of Carrión’s disease suggest complex adaptations
by the bacterium to the human host, with the overall objectives of persistence, maintenance of a reservoir state for vectorial
transmission, and immune evasion. These events include a multitude of biochemical and genetic mechanisms involving both
bacterial and host proteins. This review focuses on proteins involved in interactions between B. bacilliformis and the human
host. Some of them (e.g., flagellin, Brps, IalB, FtsZ, Hbp/Pap31, and other outer membrane proteins) are potential protein antigen
candidates for a synthetic vaccine.

1. Introduction
Bartonella bacilliformis is a member of the alpha-2 subgroup
of Proteobacteria and is the etiologic agent of Carrión’s
disease or Oroya fever in humans. Bartonellosis has been
historically described in Peru, Ecuador, and Colombia [1,
2], with Peru considered the most important endemic area
in the world. This disease often, but not always, presents
in a biphasic manner. The primary, life-threatening acute
phase is characterized by a septic state worsened by a severe
hemolytic anemia (bacteria invade the erythrocytes which
are destroyed by the spleen) [3]. This phase, known as Oroya
fever, has a high fatality rate (up to 88%) if not treated and is
more common in children [4]. Fever, pallor, general malaise,
myalgia, headache, jaundice, and hepato/splenomegaly are
the main symptoms of Oroya fever [1]. Some patients
develop, as a consequence of the septic state, a transient
immunosuppression that results in the onset of opportunistic
infections such as toxoplasmosis, tuberculosis, salmonellosis,
shigellosis, histoplasmosis, malaria, and pneumocystosis [1,

5, 6]. In the secondary chronic phase, known as verruga
peruana (Peruvian wart), the bacteria invade the endothelial
cells producing wart-like hemangiomatous lesions of the skin
and mucous membranes 4 to 8 weeks after the onset of Oroya
fever. The duration of the eruptive phase is 3 to 6 months.
Lesions are classified as miliary (small reddish papules
< 3 mm in diameter), mular (nodular tumors > 5 mm),
and diffuse subdermal nodules [7]. Inhabitants, especially
schoolchildren, in endemic regions often develop the eruptive phase as the sole manifestation of the disease [8]. Humans
are the only known natural reservoir for B. bacilliformis [7, 9].
B. bacilliformis is believed to be transmitted to humans by
bites of phlebotomine sand flies living in the high mountain
valleys of the Andes [10].
Since B. bacilliformis was first described in 1905 by
Alberto Barton; numerous research studies have been
reported, including clinical and experimental studies. In the
last 25 years, arguably the most important studies have been
conducted to explain the physiopathology of the disease.
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Figure 1: Various protein antigens of B. bacilliformis and their locations in the cell. Brp’s: Bartonella repeat proteins, FtsZ: cell division protein,
Hbp’s: hemin-binding proteins, IalB: invasion-associated locus B protein, LppB: lipoprotein B, OM: outer membrane, PG: peptidoglycan, and
CM: cytosolic membrane.

The notable differences in clinical presentations during
a B. bacilliformis infection suggest a complex adaptation to
the human host with the objectives of persistence, maintenance of a reservoir state for vector-based transmission, and
immune evasion. The bacterium-host relationship evokes a
multitude of biochemical and genetic mechanisms involving
both bacterial and host proteins.
This review focuses on proteins involved in B. bacilliformis’ interactions with the human host. We hypothesize that
certain proteins would be ideal protein antigen candidates to
be included in a chemically synthesized vaccine to block B.
bacilliformis interactions with host cells (see Figure 1).
Flagellin. B. bacilliformis cells are highly motile by lophotrichous flagella, appendages consisting of ∼42 kDa flagellin
protein subunits that are resistant to protease or trypsin
treatment [11]. B. bacilliformis was reported to possess 1 to
10 polar flagella 3 to 10 𝜇m in length [11]. In addition to
blood flow within the circulatory system, flagella provide the
bacterium with a high degree of mobility and may serve to
propel the pathogen during its search for erythrocytes [12].
Bacterial motility seems to be required for internalization,
since entry of nonmotile B. bacilliformis was not observed in
the experiments of Mernaugh and Ihler [13].
Antiserum to flagella significantly reduced B. bacilliformis
association with red cells as compared to controls [11], and
there was poor adherence of nonmotile variants and flagellinminus (bald) mutants [14, 15]. These data suggest that flagella
may possess adhesive qualities and/or they increase bacteriahost cell interactions [11]. In view of the significant decrease
in erythrocyte infection due to antiflagellin antibodies, this
protein is a promising antigen for use in a potential subunit
vaccine.
Brps. Bartonella species invade a variety of eukaryotic cells
by employing trimeric autotransporter adhesion proteins

(TAAs) [16]. The TAAs all use a type V secretion pathway
and consist of a passenger domain and a beta domain used
to deliver the passenger component out of the cell via the
outer membrane. B. bacilliformis possesses three brp genes
encoding potential Bartonella repeat proteins (Brps) [17].
B. bacilliformis Brp proteins share common domains and
structural features with the TAAs. While the biological role
of B. bacilliformis Brp proteins has not yet been investigated,
they may be involved in similar biological processes as the
TAA proteins of B. henselae and B. quintana, including
autoagglutination, adhesion to host cells and extracellular
matrix proteins (fibronectin and collagens), inhibition of
phagocytosis, and induction of a proangiogenic response in
host cells [10]. Immune-mediated inhibition of these hypothetical functions could possibly confer protection against the
pathogen.
IalB. The invasion-associated locus B (IalB) protein (see
Figure 2) was originally discovered by screening a B. bacilliformis genomic library for erythrocyte-invasive strains of
host E. coli [18]. IalB has a significant effect on enhancing
B. bacilliformis’ erythrocyte invasion. It is possible that
environmental changes during passage of the bacterium
from sand fly to humans (e.g., changes in temperature, iron
availability, and pH) have an effect on ialB gene expression
[19]. In other research, IalB protein levels were correlated with
changes in ialB mRNA and changes of temperature/pH of the
growth media. The greatest amount of ialB was present in
B. bacilliformis that had been acid-shocked (pH 5), grown at
20∘ C, or temperature downshifted to 20∘ C from 30∘ C. As with
ialB mRNA levels, IalB protein amounts in B. bacilliformis
decreased in response to basic pH (pH 8.0) or a temperature
upshift to 37∘ C [20].
Presumably, B. bacilliformis undergoes a temperature
shift from 37∘ C to 20∘ C when it is ingested by a sand fly, as
the blood meal in the insect cools to ambient temperature.

International Journal of Peptides

3

2. Miscellaneous Outer Membrane Proteins

Figure 2: Crystal structure of the invasion-associated locus
B protein; 144 residues (77% of Bartonella bacilliformis IalB
sequence) modeled with 100.0% confidence by the single highest scoring template. Program Phyre2 at http://www.sbg.bio.ic.ac
.uk/phyre2/html/page.cgi?id=index. Model based on B. henselae
IalB crystal template c3dtdi .

Concurrent with this temperature downshift, bacterial ialB
expression would presumably be upregulated for erythrocyte
invasion following transfer to another human host when the
insect subsequently feeds. A change of the pH also occurs
in the sand fly midgut (pH increases slightly to pH 7.4),
where ialB expression would presumably be upregulated.
When bacteria pass from the sand fly vector to a human
host, the event would be signalled by a rapid upshift in
temperature to 37∘ C and an increase in pH to 7.4. The ialB
gene expression would be downregulated but not abrogated
under these conditions. Undoubtedly, other bacterial factors
are involved in erythrocyte adherence and invasion. IalB was
localized to the inner membrane of B. bacilliformis, where it
is unlikely to directly interact with erythrocytes. In contrast,
the IalB homolog of B. henselae was localized to both inner
and outer membrane fractions of the bacterium [21]. It is
unknown if this protein is a transporter or signal transducer
involved in human erythrocyte invasion, and its mechanism
of action remains elusive [20].
FtsZ. The FtsZ protein of B. bacilliformis (FtsZBb) is a
∼75 kDa protein and a structural homolog of B. henselae’s cell
division protein, FtsZ [20]. FtsZBb is strongly immunogenic
in humans and was one of two major antigens (i.e., 75 kDa
and 65 kDa proteins) identified in early work [9, 22]. In
addition, the C terminus of FtsZBb contains a 256-amino acid
region that is unusual and found in other related bacteria
such as Rhizobium meliloti. As a result, the FtsZBb is almost
twice as large as the majority of the FtsZ homologs, perhaps
contributing to its antigenicity [17]. Interestingly, the ftsZ
gene has been included in MLST schemes to study clonal and
evolutionary relatedness of B. bacilliformis strains [23].

Several B. bacilliformis outer membrane proteins have been
identified by a variety of means. Minnick identified 14
proteins ranging from 11.2 to 75.3 kDa. Three of these proteins
(31.5, 42, and 45 kDa) were prominent immunoprecipitants
when they were exposed to rabbit hyperimmune serum [24].
Iwaki-Egawa and Ihler identified six B. bacilliformis proteins
that mediate bacterial interactions with erythrocytes (100, 92,
84, 46, 37, and 12 kDa) [25].
A 43 kDa immunogenic lipoprotein of B. bacilliformis
was identified through screening of a genomic DNA lambda
library. The protein is a homolog to the LppB proteins of
Haemophilus spp. and the NlpD protein of E. coli and was thus
designated LppB [24]. The LppB lipoprotein is likely to use
the same biosynthetic pathway as other bacterial lipoproteins.
The protein’s prominent immunogenicity was demonstrated
using five convalescent sera from patients with Oroya fever
or verruga peruana [26].
Buckles and McGinnis Hill demonstrated that B. bacilliformis was able to bind to several human erythrocyte proteins, including 𝛼 and 𝛽 subunits of spectrin, band 3 protein,
glycophorin A, and glycophorin B [27]. Band 3 is a major
transmembrane glycoprotein of the erythrocyte membrane,
and it may be one of the possible erythrocyte receptors of B.
bacilliformis [27]. In addition, band 3 has been suggested to
be involved Plasmodium invasion of erythrocytes [28, 29].

3. Hemin-Binding Proteins (Hbp’s)
The B. bacilliformis hemin-binding proteins (Hbp’s) are
homologs of the bacteriophage-associated, Pap31, protein of
Bartonella henselae [30] and the five hemin-binding proteins
of B. quintana [31, 32]. B. bacilliformis possesses three,
tandem hbp-encoding genes in its chromosome. In addition
to serving as a receptor for hemin and associating with the
phage coat, data from work with B. henselae suggest that
these proteins may also serve as adhesins for fibronectin,
heparin, and host cells such as endothelial cells [33]. The Hbp
(Pap31) proteins are highly expressed antigens in growing
cultures of B. bacilliformis and are immunologically dominant, making them ideal antigens for use in enzyme-linked
immunosorbent assays (ELISAs) and in immunoblots. In
fact, use of this single protein antigen permits the use of
ELISA, Western blot methods, or rapid lateral flow assay for
the diagnosis of a B. bacilliformis infection [34]. To what
extent B. bacilliformis Hbp’s are immunoreactive in humans
is unknown. However, the HbpE homolog of B. quintana is
a commonly recognized antigen in sera from trench fever
patients [35]. This observation suggests that one or more B.
bacilliformis Hbp’s may also be seroreactive in humans and
thus useful subunit vaccine candidates.

4. Conclusions
B. bacilliformis infection represents an interesting model of
human host specificity by a bacterium. While we now know
more about the biology of the bacterium and the pathogenesis
of Carrión’s disease, we still lack adequate knowledge to select
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specific protein candidates to generate a subunit vaccine
formulation. Studies regarding comparative genomics and
proteomics are sorely lacking, especially considering the
significant impact that bartonelosis outbreaks represent for
the affected populations in South America. Carrión’s disease
is an emerging infectious disease that is not amenable to
eradication with antibiotics or pesticides. Thus, the most
effective intervention strategy to improve public health will
be the development of a vaccine. Advances in B. bacilliformis
genomics and proteomics hold the promise a rational vaccine
design in the near future [36].
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